Qian Fenglei Restructures Capital Market with "FO-X" Strategy: Acquires 600 Million HKD Stake to Take Control of WellCell, Aiming for Trillion-Dollar Web3 Ecosystem

HONG KONG, May 9, 2025 /PRNewswire/ -- When traditional capital meets the Web3.0 wave, a disruptive capital

Inaugural Asia FII PRIORITY Summit Powered By FII Institute To Take Place In Hong Kong On 7 & 8 December

Inaugural Asia FII PRIORITY Summit Powered By FII Institute To Take Place In Hong Kong On 7 Paul Chan,

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1

Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025

SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene",

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

HKBN Announces the Retirement of the former Board Chairman Bradley Jay Horwitz and Appointment of Cordelia Chung as the New Board Chairman

HONG KONG, Dec. 20, 2024 /PRNewswire/ -- HKBN Ltd. ("HKBN" or the "Company"; SEHK stock

DATE OF BOARD MEETING AND DATE OF ANNOUNCEMENT OF FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS